Publications

While the DMA may be motivated by Europe’s commitment to its long-held ordoliberal model of competition policy, its disproportionate effects on U.S. firms are intentional.

The administration should address concerns related to counterfeit products, discriminatory digital taxes, and investment controls for critical technologies with measures to protect American innovation while promoting fair, rules-based trade principles that benefit the U.S. economy and support U.S. technological leadership.

The administration should address mercantilist policies that systematically disadvantage American businesses and workers with corrective measures such as strategic enforcement actions, reciprocal tariffs, expanded trade agreements, and stronger digital trade protections.

The administration should address trade imbalances, discriminatory regulations, and digital trade restrictions imposed by China, India, and the European Union, among others. Targeted policy responses may include reciprocal tariffs, digital trade enforcement, fair pricing mechanisms, and strengthened trade agreements to ensure a level playing field for U.S. businesses.

A recent report found that doubling the international Internet bandwidth for a country by installing submarine cables will decrease the cost of fixed and mobile broadband by as much as 14 and 21 percent, respectively.

America should reconsider its antagonistic approach toward Big Tech, instead forging strategic partnerships with these firms—similar to China's recent pivot—to maintain global technological leadership and competitive edge in critical fields like AI and semiconductors.

Trump and Musk are disrupting America’s scientific community, giving Canada a rare opportunity to attract top talent and position itself as a global innovation powerhouse.

In this episode of the Trade War Podcast by the Information Technology and Innovation Foundation, host Stan McCoy delves into the current state of US-EU trade tensions with esteemed European trade experts Ignacio Garcia Becerro and Aslak Berg.

Follow-on biopharmaceutical innovations deliver substantial health and economic benefits by improving the safety and efficacy of existing therapies, addressing unmet patient needs, expanding therapeutic applications, and enhancing adherence. Supportive policies are essential to sustain progress and ensure broad access to these medical advances.

The Center for Data Innovation outlined seven policy priorities we believe to be most critical for the AI Action Plan, along with specific actions the administration should take.